Loading
AI
Atreca, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Orwin John A, was filed 17 Apr 2024.
Atreca, Inc.: what insiders have been doing
Atreca, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of Atreca, Inc. in twelve months, the latest record being from 17 April 2024.
Since 2021, the database holds 1 purchase and 13 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
25
Thresholds
n/a
Buy Volume
€0
1 ops. · all time
Sell Volume
€261,876
13 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$83.7M
Last declaration on 17 April 2024
Declarations25 total
1 shares@ US$0.010.0% of flowSeries A Junior Preferred StockSEC:0001415889-24-011059:0
Canonical exit: 10 Jul 2024 (T+90)
7,061 shares@ US$0.374614.0% of flowClass A Common StockSEC:0001415889-24-010236:0
20,788 shares@ US$0.070.7% of flowClass A Common StockSEC:0001415889-24-010254:0
8,393 shares@ US$0.37461.6% of flowClass A Common StockSEC:0001415889-24-010240:0
22,951 shares@ US$0.374617.5% of flowClass A Common StockSEC:0001415889-24-010243:0
22,837 shares@ US$0.4025100.0% of flowClass A common stockSEC:0001209191-23-053345:0
4,076 shares@ US$0.952220.3% of flowClass A Common StockSEC:0001209191-23-044682:0
4,076 shares@ US$0.9522100.0% of flowClass A Common StockSEC:0001209191-23-044683:0
5,487 shares@ US$0.95222.6% of flowClass A Common StockSEC:0001209191-23-044685:0
5,487 shares@ US$0.952225.9% of flowClass A Common StockSEC:0001209191-23-044684:0
32,500 shares0Class A Common StockSEC:0001209191-23-008953:0
43,750 shares0Class A Common StockSEC:0001209191-23-008956:0
32,500 shares0Class A Common StockSEC:0001209191-23-008954:0
43,750 shares0Class A Common StockSEC:0001209191-23-008957:0
6,432 shares@ US$1.775265.7% of flowClass A Common StockSEC:0001209191-22-050776:0
7,646 shares@ US$1.775274.1% of flowClass A Common StockSEC:0001209191-22-050777:0
20,908 shares@ US$1.775282.5% of flowClass A Common StockSEC:0001209191-22-050778:0
7,646 shares@ US$1.77527.3% of flowClass A Common StockSEC:0001209191-22-050779:0
15,000 shares@ US$2.017715.4% of flowClass A Common StockSEC:0001209191-22-039949:0
30,000 shares@ US$5.0072.5% of flowClass A Common StockSEC:0001209191-22-017137:0
50,000 shares0Class A Common StockSEC:0001209191-21-057958:0
35,500 shares0Class A Common StockSEC:0001209191-21-055807:0
115,400 shares0Class A Common StockSEC:0001209191-21-055809:0
42,200 shares0Class A Common StockSEC:0001209191-21-055808:0
42,200 shares0Class A Common StockSEC:0001209191-21-055806:0
25 of 25 declarations
About Atreca, Inc.
Atreca, Inc. is a U.S.-based biotechnology company historically listed on the NASDAQ market in the United States under the ticker BCEL, before moving out of the listed market in 2024 as part of an asset sale and orderly liquidation process. The company was built around a differentiated scientific thesis: leveraging the active human immune response to discover novel antibodies and therapeutic candidates, primarily in oncology and immunology. Its headquarters and operating footprint have historically been in California, with SEC filings showing San Carlos and South San Francisco at different points in time.
From a business-model perspective, Atreca developed as a clinical-stage biotech rather than a commercial-stage pharma company. Its core lines of activity centered on antibody discovery, translational research, and the advancement of internally generated therapeutic assets. That makes the company structurally different from revenue-generating healthcare names: value creation depended on the success of preclinical and clinical development, the attractiveness of its discovery platform, and the ability to secure partnerships, licensing deals, or asset monetizations. In the crowded U.S. biotech landscape, Atreca’s competitive position was based on the novelty of its discovery approach and its immunology expertise, but it also carried the usual small-cap biotech risks: financing needs, clinical uncertainty, and dependence on capital markets.
Read moreShow less
Recent developments materially changed the investment case. In late 2023, Atreca announced a definitive agreement to sell substantially all of its antibody-related assets to Immunome, followed by a plan to liquidate and dissolve the company. SEC filings in 2024 indicate that shareholders were asked to approve both the asset sale and the dissolution plan. That sequence suggests the company transitioned from operating as a development-stage biotech to monetizing its remaining assets and winding down operations. For investors, that is a crucial distinction: the focus is no longer on commercial expansion, but on the final realization of asset value, potential contingent consideration, and the resolution of any residual obligations.
For SEO and market-context purposes, Atreca should be described as a United States biotech company associated with the NASDAQ market, with a history centered on antibody discovery and immune-response-driven therapeutics, and with recent corporate actions pointing to liquidation rather than ongoing operating growth. In that context, any insider Form 4 activity is best interpreted against a backdrop of wind-down, asset sales, and final capital allocation decisions rather than a conventional growth story.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
